ALNY
$208.56
Alnylam Pharmaceuticals
($.73)
(.35%)
ALNY
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($1.51)
Revenue:  $218.54 Mil
Thursday
Oct 28
8:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ALNY reports earnings?
Beat
Meet
Miss

Where is ALNY's stock price going from here?
Up
Flat
Down
Stock chart of ALNY
Analysts
Summary of analysts' recommendations for ALNY
Score
Grade
Pivots
Resistance
$212.86
$211.53
$210.04

$208.71

Support
$207.22
$205.89
$204.40
Tweet
Growth
Description
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
Peers
Vertex PharmaceuticalsUltragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbInterCeptMerck & Co.Eli LillyZoetisPfizer